Compare LIVE & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LIVE | IFRX |
|---|---|---|
| Founded | 1968 | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.2M | 60.6M |
| IPO Year | 1998 | 2017 |
| Metric | LIVE | IFRX |
|---|---|---|
| Price | $11.20 | $0.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 4.8K | ★ 171.7K |
| Earning Date | 05-18-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 158.14 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,054.36 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.25 | $0.71 |
| 52 Week High | $25.88 | $1.94 |
| Indicator | LIVE | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 27.02 | 52.69 |
| Support Level | $9.05 | $0.75 |
| Resistance Level | $18.99 | $1.16 |
| Average True Range (ATR) | 1.04 | 0.07 |
| MACD | -0.29 | 0.01 |
| Stochastic Oscillator | 0.00 | 50.85 |
Live Ventures Inc is a holding company of diversified businesses. It acquires and operates companies with a history of earnings power across five segments: Retail-Entertainment, Retail-Flooring, Flooring Manufacturing, Steel Manufacturing, and Corporate & Other. Retail-Entertainment offers new and pre-owned movies, video games, music, books, comics and collectibles through an integrated buy-sell-trade model. Retail-Flooring is a retailer and installer of flooring, carpeting, and countertops, serving consumers, builders, and contractors. Flooring Manufacturing produces and distributes carpet and hard-surface flooring. Steel Manufacturing engages in steel production and fabrication, generating the majority of revenue. Corporate & Other covers corporate costs and legacy products and services.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.